BDMD - bairdmed.com Debt to Book Capitalization Ratio

Corporate company logo of Baird Medical Corp (BDMD)

Baird Medical Investment (BDMD) dominates the minimally invasive tumor treatment niche, focusing on the B2B segment. This leverage chart, measuring debt to book capitalization, confirms financial stability, where 0.53 determines the current value of the metric. High-tech facilities in China drive the expansion of ablation systems. Haiyan Li's strategic direction and success with US regulatory approvals strengthen the management's international position.

Baird Medical Investment Holdings - BDMD Debts to Book Capitalization (period 10/03/2024 - 10/28/2026)
Flagship merchandise of Baird Medical Investment Holdings

Evaluating the stability of Baird Medical Investment (BDMD), I am analyzing the debt-to-book value of equity ratio. This coefficient measures the degree of financial leverage through the dynamics of equity revaluation relative to liabilities. The historical debt-to-book capitalization ratio allows for the identification of hidden risks prior to official reports. Low leverage minimizes threats to shareholders. This is critical for the microwave ablation leader, whose innovative outpatient treatment model requires stable financing without an excessive debt load.

Competitors of Baird Medical Investment

DXCM: Debts to Book Capitalization|penumbrainc.com - Debts to Book Value|Debt to Book Capitalization Ratio Novanta (NOVT)|HAE - Debt to Net Assets Ratio|INSP: Debts to Book Capitalization|PRCT (Procept) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CONMED Corporation CNMD|Debts to Book Capitalization Ratio pulsebiosciences.com|InMode - Debts to Book Capitalization|Debts to Book Value Picard Medical Corp PMI|Debt to Book Value SRDX (Surmodics Corp)|SENS - Debts to Book Capitalization|Debt to Book Value NeuroPace, Inc. NPCE|TCMD - Debt to Book Capital|SANUWAVE - Debts to Book Capitalization|Outset Medical Inc (OM) - Debts to Net Assets|Debts to Book Capitalization ELMD|Debt to Book Value LENSAR Inc (LNSR)|AVITA Medical, Inc. (RCEL) - Debt to Book Value|Debt to Net Assets Ratio PROF (profoundmedical.com)|EDAP TMS - Debt to Book Capitalization Ratio|Debt to Book Value Apyx Medical Corp APYX|ICCM (IceCure Medical, Ltd.) - Debts to Book Capitalization|LUNG - Debts to Book Value|Debts to Book Capitalization telabio.com|CytoSorbents Corporation (CTSO) - Debt to Book Value Ratio|SRTS: Debts to Book Capitalization|Debts to Net Assets Zynex Medical|Debts to Book Capitalization ECOR (electroCore, Inc.)|Debt to Book Value vicarioussurgical.com (RBOT)|Debts to Book Capitalization IINN (Inspira Technologies)|seastarmedical.com - Debts to Book Capitalization|IRIX - Debt to Book Capitalization Ratio|Intelligent Bio Solutions (INBS) - Debt to Book Capitalization Ratio|Debt to Book Value beyondair.net XAIR|Profusa, Inc (PFSA) - Debt to Net Assets Ratio|Debts to Book Capitalization SSKN (STRATA Skin Sciences Inc.)|Debts to Book Value GCTK|NAOV: Debt to Book Capitalization Ratio|Debt to Net Assets Venus Concept Inc VERO|Debt to Book Value NUWE (CHF Solutions)|Debts to Book Capitalization Aethlon Medical Corp AEMD|Debts to Book Capitalization ASXC (TransEnterix)|AVGR: Debts to Net Assets|Debt to Book Capitalization Ratio Biosig Technologies (BSGM)|CUTR (Cutera Inc.) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio KNW|Debt to Book Value Inari Medical Corp|Nevro Corp. - Debts to Book Capitalization|Debts to Book Value RSLS (reshapelifesciences.com)|SILK - Debt to Book Capitalization Ratio